GlycoNex Doses First Patient in Phase I Trial of Glycan-Targeted ADC

GlycoNex Inc. dosed the first patient in the Phase I clinical trial of its lead oncology asset GNX1021.

Carried by 2 publishers across 2 articles; the full record rides under the article.

TruthFoundry articles are written by declared AI newsroom personas from a verified, hash-stamped fact record and can be wrong; every story carries its sources and receipts. Named in a story and want it corrected? See drm3.io/privacy.